Adarza BioSystems Raises Another $25 Million to Launch Platform for Research and Drug Development

Biotech company Adarza BioSystems has announced that it has raised $25 million in a Series D round co-led by 3×5 Partners, based in Portland, Oregon, and St. Louis-based Lightchain Capital the family office of Scottrade founder Rodger Riney.

Adarza plans to use the funds to support the full commercialization of ZIVA, its automated biological testing platform for academic and clinical research. Scheduled for commercial launch in June, the ZIVA platform will allow researchers to quickly identify inflammation, cardiovascular, and oncology protein biomarkers for disease profiling and drug development.

โ€œOther testing platforms fall short,โ€ said 3×5 Partners Managing Director Joe Biller. โ€œBecause of its speed, automation, and simplicity, we see immense opportunity with Adarzaโ€™s technology, particularly when it comes to drug development and personalized medicine.โ€

Adarzaโ€™s technology includes a bench-top instrument and a portfolio of multiplexed assays that can assess hundreds of protein biomarkers simultaneously from a single biological sample, like tissue or blood, according to Bryan Witherbee, Adarzaโ€™s president and CEO. Using proprietary methods to create arrays of biologically active molecules on silicon chips, an endless number of targets can be detected in a single test, including antibodies, nucleic acids, peptides, and whole viruses/bacteria.

St. Louis-based biotech company Wugen is already using the ZIVA platform as it develops gene-editing technologies to develop cell therapies for cancer treatment.

โ€œAdarzaโ€™s ZIVA immunoassays are enabling us to follow more biomarkers, helping us speed up our ability to develop allogeneic CAR-T therapies,โ€ said John McKearn, Ph.D., CEO of Wugen.

With todayโ€™s Series D funding, Adarza has raised a total of $54 million.

Earlier round investors in Adarza include BioGenerator, RiverVest Venture Partners, Cultivation Capital, and Lewis & Clark Ventures.

With the Series D close, Adarza is adding two new board members: Drew Dennison, managing director for St. Louis-based Lightchain, and Joe Biller, 3×5 Partners managing director.

Adarza is also in the process of expanding its team to support commercialization efforts in 2020.

Jonathan Allen is the Publisher and Editor-in-Chief of EQ. Formerly the President and Co-founder of Longneck & Thunderfoot (L&T), a brand publishing company incubated at the Columbia University Startup Lab in NYC, Jonathan moved to St. Louis in the summer of 2016 after receiving an Arch Grant.

๐Ÿš€ Startup Funding News

T-REX Awarded $500k Grant to Incubate XR Tech

Wash U’s Holekamp Seed Fund Awards $1000 to Kickstart 9 Student Ventures

๐ŸŽ๏ธ Startup Accelerator News

1ST50K Grant Competition Finalists Head to Cape Girardeau

No STL Startups Join Wells Fargo Innovation Incubator in 2021

Recent Posts

Pluton Biosciences and Bayer AG to Investigate Microbial-Based Carbon Capture

Pluton Biosciences Accepted into Plug and Play AgTech Accelerator

Popular Posts

How Arch Grantโ€™s Recipient Hemadvance Attracted its Startup Dream Team

Kingdom Capital Collaborates with Washington University School of Medicine to Launch Augmented Intelligence Company PercayAI

Can St. Louis Become the Next Bioscience Hub?

12 Fundraising Tips for BioTech Companies from Cultivation Capital’s Life Sciences Fund